Jocil Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 13, 2025, 4:56 am

Quick Insight

Jocil Ltd, operating in the organic chemicals sector, currently shows a market price of 161 with a market cap of 143 Cr. The high P/E ratio of 120 indicates a potentially overvalued stock, while the ROE stands at 0.48% and ROCE at 0.71%, reflecting moderate returns on equity and capital employed. With a low OPM of 1.39% and a substantial net profit of 1 Cr, the company's operational efficiency may require scrutiny. The strong promoter holding of 55.02% offers stability, but the absence of FII investments raises questions about external confidence. Overall, Jocil's financial health appears stable, yet investors should closely monitor operational performance and market valuation.

Competitors of Jocil Ltd

All Competitor Stocks of Jocil Ltd

Quarterly Result

Last Updated: August 20, 2025, 8:30 am

Below is a detailed analysis of the quarterly data for Jocil Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 269.94 Cr.. The value appears strong and on an upward trend. It has increased from 178.15 Cr. (Mar 2025) to 269.94 Cr., marking an increase of 91.79 Cr..
• For Expenses, as of Jun 2025, the value is 266.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 176.76 Cr. (Mar 2025) to 266.18 Cr., marking an increase of 89.42 Cr..
• For Operating Profit, as of Jun 2025, the value is 3.76 Cr.. The value appears strong and on an upward trend. It has increased from 1.39 Cr. (Mar 2025) to 3.76 Cr., marking an increase of 2.37 Cr..
• For OPM %, as of Jun 2025, the value is 1.39%. The value appears strong and on an upward trend. It has increased from 0.78% (Mar 2025) to 1.39%, marking an increase of 0.61%.
• For Other Income, as of Jun 2025, the value is 0.49 Cr.. The value appears to be declining and may need further review. It has decreased from 0.68 Cr. (Mar 2025) to 0.49 Cr., marking a decrease of 0.19 Cr..
• For Interest, as of Jun 2025, the value is 0.06 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.06 Cr..
• For Depreciation, as of Jun 2025, the value is 1.22 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.42 Cr. (Mar 2025) to 1.22 Cr., marking a decrease of 0.20 Cr..
• For Profit before tax, as of Jun 2025, the value is 2.97 Cr.. The value appears strong and on an upward trend. It has increased from 0.59 Cr. (Mar 2025) to 2.97 Cr., marking an increase of 2.38 Cr..
• For Tax %, as of Jun 2025, the value is 25.25%. The value appears to be increasing, which may not be favorable. It has increased from 22.03% (Mar 2025) to 25.25%, marking an increase of 3.22%.
• For Net Profit, as of Jun 2025, the value is 2.22 Cr.. The value appears strong and on an upward trend. It has increased from 0.45 Cr. (Mar 2025) to 2.22 Cr., marking an increase of 1.77 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.50. The value appears strong and on an upward trend. It has increased from 0.51 (Mar 2025) to 2.50, marking an increase of 1.99.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 5:05 pm

Growth

Last Updated: September 5, 2025, 8:25 am

Balance Sheet

Last Updated: June 16, 2025, 11:53 am

Below is a detailed analysis of the balance sheet data for Jocil Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
• For Reserves, as of Mar 2025, the value is 197.00 Cr.. The value appears to be declining and may need further review. It has decreased from 202.00 Cr. (Mar 2024) to 197.00 Cr., marking a decrease of 5.00 Cr..
• For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 6.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 6.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 82.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 62.00 Cr. (Mar 2024) to 82.00 Cr., marking an increase of 20.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 288.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 279.00 Cr. (Mar 2024) to 288.00 Cr., marking an increase of 9.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2024) to 37.00 Cr., marking a decrease of 4.00 Cr..
• For CWIP, as of Mar 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 8.00 Cr., marking an increase of 7.00 Cr..
• For Investments, as of Mar 2025, the value is 30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2024) to 30.00 Cr., marking a decrease of 7.00 Cr..
• For Other Assets, as of Mar 2025, the value is 212.00 Cr.. The value appears strong and on an upward trend. It has increased from 200.00 Cr. (Mar 2024) to 212.00 Cr., marking an increase of 12.00 Cr..
• For Total Assets, as of Mar 2025, the value is 288.00 Cr.. The value appears strong and on an upward trend. It has increased from 279.00 Cr. (Mar 2024) to 288.00 Cr., marking an increase of 9.00 Cr..

Notably, the Reserves (197.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Jocil Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 1.94. This value is below the healthy minimum of 5. It has decreased from 11.25 (Mar 23) to 1.94, marking a decrease of 9.31.
• For Diluted EPS (Rs.), as of Mar 24, the value is 1.94. This value is below the healthy minimum of 5. It has decreased from 11.25 (Mar 23) to 1.94, marking a decrease of 9.31.
• For Cash EPS (Rs.), as of Mar 24, the value is 8.81. This value is within the healthy range. It has decreased from 18.25 (Mar 23) to 8.81, marking a decrease of 9.44.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 237.10. It has increased from 232.39 (Mar 23) to 237.10, marking an increase of 4.71.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 237.10. It has increased from 232.39 (Mar 23) to 237.10, marking an increase of 4.71.
• For Dividend / Share (Rs.), as of Mar 24, the value is 1.50. This value is within the healthy range. It has decreased from 2.50 (Mar 23) to 1.50, marking a decrease of 1.00.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 848.04. It has decreased from 1,035.04 (Mar 23) to 848.04, marking a decrease of 187.00.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 10.22. This value is within the healthy range. It has decreased from 22.62 (Mar 23) to 10.22, marking a decrease of 12.40.
• For PBIT / Share (Rs.), as of Mar 24, the value is 3.35. This value is within the healthy range. It has decreased from 15.63 (Mar 23) to 3.35, marking a decrease of 12.28.
• For PBT / Share (Rs.), as of Mar 24, the value is 2.98. This value is within the healthy range. It has decreased from 14.35 (Mar 23) to 2.98, marking a decrease of 11.37.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 1.94. This value is below the healthy minimum of 2. It has decreased from 11.25 (Mar 23) to 1.94, marking a decrease of 9.31.
• For PBDIT Margin (%), as of Mar 24, the value is 1.20. This value is below the healthy minimum of 10. It has decreased from 2.18 (Mar 23) to 1.20, marking a decrease of 0.98.
• For PBIT Margin (%), as of Mar 24, the value is 0.39. This value is below the healthy minimum of 10. It has decreased from 1.50 (Mar 23) to 0.39, marking a decrease of 1.11.
• For PBT Margin (%), as of Mar 24, the value is 0.35. This value is below the healthy minimum of 10. It has decreased from 1.38 (Mar 23) to 0.35, marking a decrease of 1.03.
• For Net Profit Margin (%), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 1.08 (Mar 23) to 0.22, marking a decrease of 0.86.
• For Return on Networth / Equity (%), as of Mar 24, the value is 0.82. This value is below the healthy minimum of 15. It has decreased from 4.84 (Mar 23) to 0.82, marking a decrease of 4.02.
• For Return on Capital Employeed (%), as of Mar 24, the value is 1.39. This value is below the healthy minimum of 10. It has decreased from 6.60 (Mar 23) to 1.39, marking a decrease of 5.21.
• For Return On Assets (%), as of Mar 24, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 3.94 (Mar 23) to 0.61, marking a decrease of 3.33.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.02. This value is within the healthy range. It has increased from 0.01 (Mar 23) to 0.02, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 2.83. It has decreased from 3.60 (Mar 23) to 2.83, marking a decrease of 0.77.
• For Current Ratio (X), as of Mar 24, the value is 3.48. This value exceeds the healthy maximum of 3. It has decreased from 4.64 (Mar 23) to 3.48, marking a decrease of 1.16.
• For Quick Ratio (X), as of Mar 24, the value is 2.02. This value exceeds the healthy maximum of 2. It has decreased from 2.74 (Mar 23) to 2.02, marking a decrease of 0.72.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 6.80. This value is within the healthy range. It has decreased from 7.74 (Mar 23) to 6.80, marking a decrease of 0.94.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 128.54. This value exceeds the healthy maximum of 50. It has increased from 17.77 (Mar 23) to 128.54, marking an increase of 110.77.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 28.35. This value is within the healthy range. It has increased from 10.96 (Mar 23) to 28.35, marking an increase of 17.39.
• For Earning Retention Ratio (%), as of Mar 24, the value is -28.54. This value is below the healthy minimum of 40. It has decreased from 82.23 (Mar 23) to -28.54, marking a decrease of 110.77.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 71.65. This value exceeds the healthy maximum of 70. It has decreased from 89.04 (Mar 23) to 71.65, marking a decrease of 17.39.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 27.47. This value is within the healthy range. It has increased from 17.68 (Mar 23) to 27.47, marking an increase of 9.79.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 6.23. This value is within the healthy range. It has decreased from 9.80 (Mar 23) to 6.23, marking a decrease of 3.57.
• For Enterprise Value (Cr.), as of Mar 24, the value is 129.34. It has decreased from 129.51 (Mar 23) to 129.34, marking a decrease of 0.17.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.17. This value is below the healthy minimum of 1. It has increased from 0.14 (Mar 23) to 0.17, marking an increase of 0.03.
• For EV / EBITDA (X), as of Mar 24, the value is 14.25. This value is within the healthy range. It has increased from 6.45 (Mar 23) to 14.25, marking an increase of 7.80.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.19. This value is below the healthy minimum of 1. It has increased from 0.14 (Mar 23) to 0.19, marking an increase of 0.05.
• For Retention Ratios (%), as of Mar 24, the value is -28.54. This value is below the healthy minimum of 30. It has decreased from 82.22 (Mar 23) to -28.54, marking a decrease of 110.76.
• For Price / BV (X), as of Mar 24, the value is 0.71. This value is below the healthy minimum of 1. It has increased from 0.65 (Mar 23) to 0.71, marking an increase of 0.06.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.19. This value is below the healthy minimum of 1. It has increased from 0.14 (Mar 23) to 0.19, marking an increase of 0.05.
• For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 23) to 0.01, marking a decrease of 0.06.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness